Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
02 août 2018 16h05 HE
|
Zafgen, Inc.
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference
01 août 2018 16h15 HE
|
Zafgen, Inc.
BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results
31 juil. 2018 16h05 HE
|
Zafgen, Inc.
BOSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study
09 juil. 2018 08h00 HE
|
Zafgen, Inc.
Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to...
Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares
02 juil. 2018 16h05 HE
|
Zafgen, Inc.
BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Announces Pricing of Offering of Common Stock
28 juin 2018 08h00 HE
|
Zafgen, Inc.
BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Announces Proposed Offering of Common Stock
27 juin 2018 16h01 HE
|
Zafgen, Inc.
BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Set to Join Russell 3000® Index
25 juin 2018 07h05 HE
|
Zafgen, Inc.
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
25 juin 2018 07h00 HE
|
Zafgen, Inc.
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
23 juin 2018 10h00 HE
|
Zafgen, Inc.
Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen...